Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care
PR95099
LONDON and NEW YORK, March 24, 2022 /PRNewswire=KYODO JBN/ --
Huma acquires AstraZeneca’s digital health platform AMAZE(TM) and AstraZeneca
becomes a shareholder of Huma
Huma Therapeutics Limited [https://www.huma.com/], a global digital health
technology company advancing digital-first care delivery and research to help
people live longer, fuller lives, today announced a new partnership with
AstraZeneca to scale innovation for digital health. This agreement follows
prior use cases executed between Huma and AstraZeneca, reflecting a shared
ambition to improve clinical outcomes through digital health solutions to
bridge the gap between patients and clinicians.
As part of this partnership, Huma and AstraZeneca will launch Software as a
Medical Device (SaMD) companion apps targeted at several therapeutic areas and
will partner to help accelerate adoption of decentralized clinical trials.
These will build on Huma’s proven technologies which already power
digital-first care serving more than 1.8 million active patient users across
more than 3,000 hospitals and clinics. Huma’s technologies are designed to
connect with clinical workflows, allowing for more efficient care delivery.
“Our track record of scaling innovation has set the stage for this important
partnership with one of the world’s largest biopharmaceutical
companies. I am excited to have AstraZeneca’s support to build upon our
10-year experience of delivering digital-first solutions across healthcare and
clinical trials,” said Dan Vahdat, CEO of Huma. “The combination of pioneering
leadership, global-reach, deep medical knowledge and digital innovation will
enable our award-winning(1) platform to help more people live longer, fuller
lives."
"This collaboration marks an important moment as it is a first for AstraZeneca
in the digital health space as well as in the industry for chronic diseases and
SaMDs in support of different treatments,” said Karan Arora, Chief Commercial
Digital Officer, AstraZeneca. “With Huma, we are accelerating AstraZeneca’s
ambition to achieve earlier diagnosis and treatment for patients with chronic
diseases so they can lead better, more fulfilling lives.”
Ninety-five percent of care for chronic conditions happens outside the clinical
setting(2), highlighting the need for more digital-first care. AstraZeneca has
invested in the development and clinical validation of the patient centered
AMAZE chronic disease management platform to improve the care of patients.
AstraZeneca has used the AMAZE platform to conduct clinical studies at leading
U.S. academic medical centers with the goals of improving patient engagement,
care-team communication and clinical outcomes while reducing healthcare costs.
The collaboration with Huma will leverage the strong foundations and early
success of AMAZETM to accelerate digital-first care across therapeutic areas
and launch SaMDs.
"We are very excited to be working more closely with Huma across our digital
health initiatives,” said Ruud Dobber, Executive Vice President and President,
Biopharmaceuticals Business Unit, AstraZeneca. “We believe digital can expand
access to healthcare, advance clinical research, and identify existing gaps in
care. Additionally, with this innovative partnership, we will bring a
combination of technology along with expertise in research and drug development
to global decentralized clinical trials advancing the science of right patient,
right therapy, right time.”
About Huma
Huma Therapeutics is a global digital health technology company that advances
digital-first care delivery and research to help people live longer, fuller
lives. Huma’s award-winning modular platforms are used by more than 3,000
hospitals and clinics, with 1.8 million active users. Huma’s offering works
across different disease areas and powers:
- ‘Hospitals at Home’
- Software as a Medical Device (SaMD) solutions
- DCT platform to support digital or hybrid studies
Huma’s platform has been shown to almost double clinical capacity3, reduce
readmissions by over a third, enable better diversity, participant retention
and protocol adherence, whilst allowing trials to run within weeks. Please
visit www.huma.com and follow us on LinkedIn at Huma
[https://www.linkedin.com/company/humaforhealth/].
References
1. Huma Therapeutics wins Prix Galien USA 2021 award
[https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fhuma.com%2Fth
oughtpiece%2Fprixgalienaward&data=04%7C01%7Crelease%40prnewswire.co.uk%7Cc70ed8e
d5bf8483c4c7a08da0b593c36%7C887bf9ee3c824b88bcb280d5e169b99b%7C1%7C0%7C637834775
135487916%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik
1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=DdIRB17F8Bt35gT%2BU9s4yo3POkSAKuBT3i31y8prx2c%
3D&reserved=0] for Best Digital Health Product
2. American Academy of Family Physicians:
https://www.aafp.org/fpm/2000/0300/p47.html
3. NHSX report:
nhsx.nhs.uk/covid-19-response/technology-nhs/huma-medopad-evaluation-remote-digi
tal-care-platform/ The full report is available on request.
Logo - https://mma.prnewswire.com/media/1427908/Huma_Logo.jpg
Source: Huma
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。